Ceretek LLC
This article was originally published in Start Up
Executive Summary
Ceretek LLC is developing new cancer therapeutic targets based on endothelial differentiation gene (Edg) receptors, a subtype of lipid GPCRs that have been shown to be up-regulated in a variety of cancers. The company has proprietary assays for all eight Edg receptors, and is developing drug candidates based on the targets it identifies.